|
Valoración de DCF Savara Inc. (SVRA)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Savara Inc. (SVRA) Bundle
Diseñada para la precisión, nuestra calculadora DCF (SVRA) le permite evaluar la valoración de Savara Inc. utilizando datos financieros del mundo real, proporcionando una flexibilidad completa para modificar todos los parámetros clave para mejorar las proyecciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | -100 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -77.1 | -47.4 | -40.4 | -37.9 | -59.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | -18459.14 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | 1.0 | .7 | .4 | .2 | .2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 269.65 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -78.1 | -48.1 | -40.7 | -38.1 | -59.3 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | -18728.79 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 121.8 | 82.2 | 161.2 | 125.9 | 162.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.6 | 1.7 | 1.1 | 1.0 | 1.0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 659.53 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | -1.6 | -1.7 | -1.1 | 2.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | -659.53 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | 3.4 | 2.6 | 1.4 | 1.3 | 3.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 1009.73 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | -3.3 | -.1 | .0 | -.3 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | -1281.71 | 100 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -104.9 | -49.6 | -42.9 | -38.9 | -59.3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -100.7 | -53.0 | -43.7 | -41.8 | -55.3 | -2.5 | .0 | .0 | .0 | .0 |
| WACC, % | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 | 9.02 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -2 | |||||||||
| Diluted Shares Outstanding, MM | 165 | |||||||||
| Equity Value Per Share | -0.01 |
What You Will Get
- Real SVRA Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess Savara Inc.'s future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive SVRA Data: Pre-filled with Savara Inc.’s historical performance metrics and future outlooks.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
- Adaptive Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecast scenarios to evaluate different valuation results.
- User-Friendly Interface: Intuitive, organized, and tailored for both industry professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Savara Inc. (SVRA) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Savara Inc.'s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Savara Inc. (SVRA)?
- Save Time: Quickly access comprehensive data without the hassle of building from the ground up.
- Enhance Accuracy: Dependable financial metrics and methodologies minimize valuation errors.
- Fully Customizable: Adjust the model to align with your specific assumptions and forecasts.
- Simple to Analyze: Intuitive graphs and outputs facilitate straightforward interpretation of results.
- Endorsed by Professionals: Crafted for experts who prioritize both precision and functionality.
Who Should Use Savara Inc. (SVRA)?
- Investors: Gain insights into the biopharmaceutical sector with a reliable investment analysis tool.
- Financial Analysts: Streamline your workflow with customizable financial models tailored for Savara Inc. (SVRA).
- Consultants: Efficiently modify the framework for client presentations or strategic reports on Savara Inc. (SVRA).
- Biotech Enthusiasts: Enhance your knowledge of the industry through detailed case studies and market analysis.
- Educators and Students: Utilize it as a hands-on resource in courses focused on biotechnology and finance.
What the Template Contains
- Pre-Filled Data: Includes Savara Inc.’s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Savara Inc.’s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.